Reporting Quality of Evaluations of Additional Risk Minimisation Measures by MAH: An Assessment of Studies Submitted in the European Union

被引：0
|
作者：
Okai, J. [1 ,2 ]
Bahri, P. [2 ]
Sarinic, V. Macolic [2 ]
机构：
[1] Univ Utrecht, Pharmaceut Sci, Utrecht, Netherlands
[2] European Med Agcy, Human Med Div, Pharmacovigilance Off, Amsterdam, Netherlands
来源：
DRUG SAFETY | 2021年 / 44卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
P003
引用
收藏
页码：1402 / 1403
页数：2
相关论文
共 28 条
  • [21] Assessment of colistimethate sodium (COLOBREATHE) risk minimization measures implemented in the European Union: A cross-sectional study
    Kaplan, Sigal
    Patino, Oliver
    Rainville, Carolyn
    Madison, Terri
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (02) : 219 - 223
  • [22] Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs
    Giampiero Mazzaglia
    Sabine M. J. Straus
    Peter Arlett
    Daniela da Silva
    Heidi Janssen
    June Raine
    Enrica Alteri
    Drug Safety, 2018, 41 : 191 - 202
  • [23] Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs
    Mazzaglia, Giampiero
    Straus, Sabine M. J.
    Arlett, Peter
    da Silva, Daniela
    Janssen, Heidi
    Raine, June
    Alteri, Enrica
    DRUG SAFETY, 2018, 41 (02) : 191 - 202
  • [24] Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study
    Landsberg, Wally
    Al-Dakkak, Imad
    Coppin-Renz, Antonia
    Geis, Uli
    Peters-Strickland, Timothy
    van Heumen, Emiel
    Rahman, Mirza
    DRUG SAFETY, 2018, 41 (08) : 797 - 806
  • [25] Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study
    Wally Landsberg
    Imad Al-Dakkak
    Antonia Coppin-Renz
    Uli Geis
    Timothy Peters-Strickland
    Emiel van Heumen
    Mirza Rahman
    Drug Safety, 2018, 41 : 797 - 806
  • [26] Challenges and recommendations in understanding national guidance and marketing authorization holder experiences for implementing additional risk minimization measures in the European Union and the United Kingdom
    Pianka, Krystle
    Parikh, Nipa
    Rahman, Mirza
    Patel, Harshil
    Dave, Jay
    Hapani, Kalindi
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 161 - 161
  • [27] Energy Poverty in European Union: Assessment Difficulties, Effects on the Quality of Life, Mitigation Measures. Some Evidences from Romania
    Neacsa, Adrian
    Panait, Mirela
    Muresan, Jianu Daniel
    Voica, Marian Catalin
    SUSTAINABILITY, 2020, 12 (10)
  • [28] Review of studies evaluating the effectiveness of risk minimization measures assessed by the pharmacovigilance risk assessment committee of the European medicines agency during 2016-2021
    Grupstra, Renske
    Goedecke, Thomas
    Gardarsdottir, Helga
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 623 - 624
123